



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 37/02, C07K 5/00, 7/00, 15/00, 17/00		A1	(11) International Publication Number: WO 95/00161
			(43) International Publication Date: 5 January 1995 (05.01.95)

(21) International Application Number: PCT/US94/06837	(31) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 16 June 1994 (16.06.94)	Published With international search report.
(30) Priority Data: 08/079,319 18 June 1993 (18.06.93) US	
(71) Applicant (for all designated States except US): UNIVERSITY OF CINCINNATI [US/US]; Mail Location 627, Cincinnati, OH 45221-0726 (US).	
(72) Inventor; and	
(73) Inventor/Applicant (for US only): BALASUBRAMANIAM, Ambikaipakan [US/US]; 2706 Lawyers Pointe Drive, Cincinnati, OH 45244 (US).	
(74) Agent: CLARK, Paul, T.; Fish and Richardson, 225 Franklin Street, Boston, MA 02110 (US).	

(54) Title: NEUROPEPTIDE Y ANTAGONISTS AND AGONISTS

(57) Abstract

The invention discloses analogs which behave as NPY antagonists and agonists; and methods of their use for controlling a biological activity such as appetite and cardiovascular function.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KR	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

NEUROPEPTIDE Y ANTAGONISTS AND AGONISTS

Background of the Invention

This invention relates to peptide derivatives
5 which are antagonists or agonists of neuropeptide Y.

Neuropeptide Y (NPY), is a 36-residue peptide characterized by a tyrosine (Y) residue at its N-terminus and a tyrosine amide residue at its C-terminus. The peptide was isolated from porcine brain (Tatemoto Proc. 10 *Natl. Acad. Sci. U.S.A.* 79:5485-5489, 1982) and is considered to be a neurotransmitter or neuromodulator widely distributed in the central and peripheral nervous systems (Allen et al., *Neurochem. Int.* 8:1-8, 1986). It is the most abundant peptide present in the mammalian 15 brain and heart (Edvinsson et al., *Trends Pharmol. Sci.* 8:231-235, 1987; Gu et al., *Histochem. Cytochem.* 32:467-472, 1984), and is among the most potent vasoconstrictor peptides isolated to date (Lundberg et al., *Acta Physiol. Scand.* 121:325-332, 1984). However, NPY elicits several 20 physiological responses by activating specific pre- and post-synaptic receptors. Centrally, NPY is thought to be involved in the regulation of food intake, memory processing and circadian rhythm (Sheikh et al., *FEBS Lett.* 245: 209-214, 1989). In the periphery, NPY seems 25 to function as a transmitter in sympathetic nerves where it interacts with norepinephrine mainly in the regulation of vasculartone (Sheikh et al. *FEBS Lett.* 245:209-214, 1989).

Different structure-activity relationships for NPY 30 analogs in various model systems have indicated that multiple NPY receptor subtypes exist (Michel, *Tips* 12:389-394, 1991). Wahlestedt and coworkers (*Regul. Pept.* 13:307-318, 1986) first suggested the existence of two distinct subtypes of NPY receptors. Post-synaptic 35 (Y₁-type) effects could be obtained with the complete NPY

- 2 -

molecule, while pre-synaptic (Y2-type) effects were found elicited by long C-terminal fragments, as well as with the entire NPY molecule. Thus, both Y1 and Y2 receptors exhibit nearly equal affinity to NPY and its homologous 5 peptide, peptide YY, but only the Y2 receptors could bind to shorter carboxyl-terminal fragments including NPY(13-36) as described by Sheikh et al. (FEBS Lett. 245:209-214, 1989). However, since NPY receptors in rat cardiac ventricular membranes discriminate between NPY and 10 peptide YY but bind NPY(13-36), it was suggested that this system be classified as a subtype of Y2 or a new class (designated Y3) of receptors as discussed below (Balasubramaniam et al. Peptides 11:545-550, 1990).

NPY is also present in high concentrations in a 15 distinct population of nerve fibers innervating the heart and blood vessels (Wharton et al., Ann. N.Y. Acad. Sci. 611:133-144, 1990). NPY is now regarded as the predominant peptide present in the cardiovascular system of mammals. This observation has led to numerous studies 20 of the cardiovascular properties of NPY. For example, several investigations have reported that NPY is a potent vasopressor peptide and that it inhibits the coronary blood flow and contractility in isolated perfused hearts (e.g., see Balasubramaniam et al., Regul. Pept. 21:289-259, 1988; Allen et al. Regul. Pept. 6:247-253, 1983; Rioux et al. Peptides 7:27-31, 1986). Furthermore, NPY is also capable of (1) inhibiting the contractile force 25 of isolated cardiac muscles (Balasubramaniam et al. supra) and myocytes (Piper et al. Nuunyn-Schniedberg's 30 Arch. Pharmol. 340: 333-337, 1989) and (2) the adenylate cyclase activity and cAMP production by cardiac muscles (Kassis et al., J. Biol. Chem. 262: 3429-3431, 1987) and myocytes (Kassis et al. supra; Millar et al. Nuunyn-Schniedberg's Arch. Pharmol. 338:426-429, 1989), 35 respectively. Specific receptors of NPY in rat cardiac

- 3 -

ventricular membranes have been characterized and reported to be more selective to NPY than previously characterized NPY receptors as discussed above (Balasubramaniam et al. *Peptides* 11:545-550, 1990). The 5 presence of specific receptors of NPY in rat cardiac membranes, the Y-3 receptor, was also reported by visualization with N^a biotinyl-NPY analogs (Balasubramaniam et al. *Peptides* 11: 1151-1155, 1990).

The following table (the abbreviations used are 10 commonly known in the art and are described *infra*) shows the amino acid homology between NPY and PYY:

		5	10	15	20	25	30	35
	Human NPY	Y	P	S	K	P	O	N
15	Rat NPY	Y	P	S	K	P	O	N
	Rabbit NPY	Y	P	S	K	P	O	N
	Guinea pig NPY	Y	P	S	K	P	O	N
	Porcine NPY	Y	P	S	K	P	O	N
	Human PYY	Y	P	I	K	P	A	P
20	Porcine PYY	Y	P	I	K	P	A	P
	Rat PYY	Y	P	I	K	P	A	P

NPY has been implicated in the pathophysiology of a number of diseases including, without limitation, obesity, hypertension and chronic heart failure (CHF) 25 because: (1) hypothalamic NPY levels are elevated in obese rats and decreased in cancer anorectic rats; (2) plasma NPY levels are elevated in CHF and hypertensive patients; (3) negative cardiac inotropic and chronotropic actions; and (4) inhibition of libido and circadian 30 rhythm. Thus, since NPY has been shown to be important for regulating a plurality of physiological events we have set out to design a series of receptor-specific analogs that selectively modulate a variety of biological activities, e.g., appetite and blood pressure activities.